The trial will investigate high-affinity natural killer cell therapy in combination with anti-cancer agents, including aldoxorubicin, in metastatic pancreatic cancer patients who have progressed on or following standard-of-care therapy.
CytRx Highlights Dosing of the First Patient in Licensee NantCell Clinical Trial Investigating Cell-Based Therapy in Combination With Multiple Anti-Cancer Agents, Including Aldoxorubicin, in Patients With Metastatic Pancreatic CancerAdditional Clinical Trials Evaluating Combinations with Aldoxorubicin Expected to Commence in 2018 |
| [17-January-2018] |
| LOS ANGELES, Jan. 17, 2018 /PRNewswire/ -- CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with metastatic pancreatic cancer. The trial will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in metastatic pancreatic cancer patients who have progressed on or following standard-of-care therapy. “NantCell’s decision to include aldoxorubicin in this new trial speaks to their commitment to expanding its potential use in combination with immuno-oncology agents and cell-based therapies,” said Steven A. Kriegsman, CytRx’s Chairman and CEO. The trial titled “QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,” (NCT03387098) is a single-center, open-label, Phase 1b/2 clinical trial designed to evaluate the safety and efficacy of several combination therapies, including combinations with aldoxorubicin, in subjects with pancreatic cancer who have progressed on or after previous standard of care chemotherapy. This trial is expected to enroll approximately 173 patients. The primary endpoint for the Phase 1b portion of the trial is safety and the primary endpoint for the Phase 2 portion of the trial is objective response rate (ORR) by RECIST. About CytRx Corporation CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx’s most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc. Forward-Looking Statements This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the Nasdaq rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADR™ technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations Contact:
SOURCE CytRx Corporation | ||
Company Codes: NASDAQ-SMALL:CYTR |
